WuXi Biologics Celebrates Sixth Year as ESG Leader by Morningstar Sustainalytics
WuXi Biologics (2269.HK), a standout Contract Research, Development and Manufacturing Organization (CRDMO), has achieved recognition from Morningstar Sustainalytics as both an Industry and Regional ESG Leader for the year 2026. This marks the sixth consecutive year that the company has been awarded this prestigious honor, affirming its ongoing commitment to integrating sustainability into all aspects of its global operations.
The recognition by Morningstar Sustainalytics, a prominent independent ESG research and analytics firm, showcases WuXi Biologics’ dedication to creating a more sustainable future. The firm’s ESG Risk Ratings evaluated around 15,000 companies across 42 industries worldwide, with WuXi Biologics standing out for its robust management of ESG risks and superior performance against its peers in both industry and region. This recognition comes off the back of WuXi Biologics being classified in Sustainalytics’ highest tier of negligible ESG risk, placing it among the top 1% globally.
CEO Dr. Chris Chen expressed pride in this achievement, highlighting the company's proactive approach to sustainability. He stated, “We are honored to once again be recognized by Morningstar Sustainalytics. Our vision as a Green CRDMO leader is brought to life through our collaboration with stakeholders to create meaningful social and environmental impacts.” He emphasized the company’s mission to make therapeutic innovations accessible and affordable, propelling the journey from molecule discovery to market more efficiently and at scale.
WuXi Biologics' ongoing efforts in sustainable development have not gone unnoticed. The company has earned numerous accolades from various ESG rating agencies, including a coveted MSCI AAA rating and an EcoVadis Platinum Medal, as well as listings in the Dow Jones Best-in-Class Indices, indicating its outstanding reputation in environmental stewardship. Additionally, for its efforts in key areas such as climate change and water security, the company received an 'A List' status by CDP, a global environmental disclosure platform.
With a workforce of over 13,000 across multiple countries including China, the United States, and Germany, WuXi Biologics prides itself on its capability to deliver scalable and effective biologics solutions. By integrating advanced digital capabilities and optimizing operations, the company continues to support a vast number of client projects—currently 945 projects that include therapies in various stages from Phase III trials to commercial manufacturing.
WuXi Biologics actively pursues its goal of fostering a robust sustainability framework, which it views as essential to long-term business success. The firm is committed to enhancing Green CRDMO solutions while promoting social responsibility through direct collaborations with various stakeholders. The company underscores its dedication to not only meeting but exceeding the expectations of its partners through responsible practices throughout its entire value chain.
As WuXi Biologics continues to lead in sustainability, it sets an example for others in the industry. The commitment to long-term value creation is evident in their focus on driving innovation that contributes positively to both society and the environment, ensuring that patients around the world benefit from their achievements. Future growth will hinge on this unwavering dedication to sustainability, technological advancement, and delivering quality biologics solutions on a global scale.
The recognition by Morningstar Sustainalytics, a prominent independent ESG research and analytics firm, showcases WuXi Biologics’ dedication to creating a more sustainable future. The firm’s ESG Risk Ratings evaluated around 15,000 companies across 42 industries worldwide, with WuXi Biologics standing out for its robust management of ESG risks and superior performance against its peers in both industry and region. This recognition comes off the back of WuXi Biologics being classified in Sustainalytics’ highest tier of negligible ESG risk, placing it among the top 1% globally.
CEO Dr. Chris Chen expressed pride in this achievement, highlighting the company's proactive approach to sustainability. He stated, “We are honored to once again be recognized by Morningstar Sustainalytics. Our vision as a Green CRDMO leader is brought to life through our collaboration with stakeholders to create meaningful social and environmental impacts.” He emphasized the company’s mission to make therapeutic innovations accessible and affordable, propelling the journey from molecule discovery to market more efficiently and at scale.
WuXi Biologics' ongoing efforts in sustainable development have not gone unnoticed. The company has earned numerous accolades from various ESG rating agencies, including a coveted MSCI AAA rating and an EcoVadis Platinum Medal, as well as listings in the Dow Jones Best-in-Class Indices, indicating its outstanding reputation in environmental stewardship. Additionally, for its efforts in key areas such as climate change and water security, the company received an 'A List' status by CDP, a global environmental disclosure platform.
With a workforce of over 13,000 across multiple countries including China, the United States, and Germany, WuXi Biologics prides itself on its capability to deliver scalable and effective biologics solutions. By integrating advanced digital capabilities and optimizing operations, the company continues to support a vast number of client projects—currently 945 projects that include therapies in various stages from Phase III trials to commercial manufacturing.
WuXi Biologics actively pursues its goal of fostering a robust sustainability framework, which it views as essential to long-term business success. The firm is committed to enhancing Green CRDMO solutions while promoting social responsibility through direct collaborations with various stakeholders. The company underscores its dedication to not only meeting but exceeding the expectations of its partners through responsible practices throughout its entire value chain.
As WuXi Biologics continues to lead in sustainability, it sets an example for others in the industry. The commitment to long-term value creation is evident in their focus on driving innovation that contributes positively to both society and the environment, ensuring that patients around the world benefit from their achievements. Future growth will hinge on this unwavering dedication to sustainability, technological advancement, and delivering quality biologics solutions on a global scale.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.